Skip to main content
Top
Published in: Breast Cancer Research 1/2006

Open Access 01-02-2006 | Research article

Analysis of cancer risk and BRCA1 and BRCA2mutation prevalence in the kConFab familial breast cancer resource

Authors: Graham J Mann, Heather Thorne, Rosemary L Balleine, Phyllis N Butow, Christine L Clarke, Edward Edkins, Gerda M Evans, Sián Fereday, Eric Haan, Michael Gattas, Graham G Giles, Jack Goldblatt, John L Hopper, Judy Kirk, Jennifer A Leary, Geoffrey Lindeman, Eveline Niedermayr, Kelly-Anne Phillips, Sandra Picken, Gulietta M Pupo, Christobel Saunders, Clare L Scott, Amanda B Spurdle, Graeme Suthers, Kathy Tucker, Georgia Chenevix-Trench, The Kathleen Cuningham Consortium for Research in Familial Breast Cancer

Published in: Breast Cancer Research | Issue 1/2006

Login to get access

Abstract

Introduction

The Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab) is a multidisciplinary, collaborative framework for the investigation of familial breast cancer. Based in Australia, the primary aim of kConFab is to facilitate high-quality research by amassing a large and comprehensive resource of epidemiological and clinical data with biospecimens from individuals at high risk of breast and/or ovarian cancer, and from their close relatives.

Methods

Epidemiological, family history and lifestyle data, as well as biospecimens, are collected from multiple-case breast cancer families ascertained through family cancer clinics in Australia and New Zealand. We used the Tyrer-Cuzick algorithms to assess the prospective risk of breast cancer in women in the kConFab cohort who were unaffected with breast cancer at the time of enrolment in the study.

Results

Of kConFab's first 822 families, 518 families had multiple cases of female breast cancer alone, 239 had cases of female breast and ovarian cancer, 37 had cases of female and male breast cancer, and 14 had both ovarian cancer as well as male and female breast cancer. Data are currently held for 11,422 people and germline DNAs for 7,389. Among the 812 families with at least one germline sample collected, the mean number of germline DNA samples collected per family is nine. Of the 747 families that have undergone some form of mutation screening, 229 (31%) carry a pathogenic or splice-site mutation in BRCA1 or BRCA2. Germline DNAs and data are stored from 773 proven carriers of BRCA1 or BRCA1 mutations. kConFab's fresh tissue bank includes 253 specimens of breast or ovarian tissue – both normal and malignant – including 126 from carriers of BRCA1 or BRCA2 mutations.

Conclusion

These kConFab resources are available to researchers anywhere in the world, who may apply to kConFab for biospecimens and data for use in ethically approved, peer-reviewed projects. A high calculated risk from the Tyrer-Cuzick algorithms correlated closely with the subsequent occurrence of breast cancer in BRCA1 and BRCA2 mutation positive families, but this was less evident in families in which no pathogenic BRCA1 or BRCA2 mutation has been detected.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, et al: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998, 62: 676-689. 10.1086/301749.CrossRefPubMedPubMedCentral Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, et al: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998, 62: 676-689. 10.1086/301749.CrossRefPubMedPubMedCentral
2.
go back to reference Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, et al: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994, 266: 66-71.CrossRefPubMed Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, et al: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994, 266: 66-71.CrossRefPubMed
3.
go back to reference Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G: Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995, 378: 789-792. 10.1038/378789a0.CrossRefPubMed Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G: Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995, 378: 789-792. 10.1038/378789a0.CrossRefPubMed
4.
go back to reference Hopper JL, Chenevix-Trench G, Jolley DJ, Dite GS, Jenkins MA, Venter DJ, McCredie MR, Giles GG: Design and analysis issues in a population-based, case-control-family study of the genetic epidemiology of breast cancer and the Co-operative Family Registry for Breast Cancer Studies (CFRBCS). J Natl Cancer Inst Monogr. 1999, 26: 95-100.CrossRef Hopper JL, Chenevix-Trench G, Jolley DJ, Dite GS, Jenkins MA, Venter DJ, McCredie MR, Giles GG: Design and analysis issues in a population-based, case-control-family study of the genetic epidemiology of breast cancer and the Co-operative Family Registry for Breast Cancer Studies (CFRBCS). J Natl Cancer Inst Monogr. 1999, 26: 95-100.CrossRef
5.
go back to reference Thorlacius S, Struewing JP, Hartge P, Olafsdottir GH, Sigvaldason H, Tryggvadottir L, Wacholder S, Tulinius H, Eyfjord JE: Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet. 1998, 352: 1337-1339. 10.1016/S0140-6736(98)03300-5.CrossRefPubMed Thorlacius S, Struewing JP, Hartge P, Olafsdottir GH, Sigvaldason H, Tryggvadottir L, Wacholder S, Tulinius H, Eyfjord JE: Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet. 1998, 352: 1337-1339. 10.1016/S0140-6736(98)03300-5.CrossRefPubMed
6.
go back to reference Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, de Snoo A, Oldenburg R, Hollestelle A, Houben M, Crepin E, van Veghel-Plandsoen M, et al: Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet. 2002, 31: 55-59. 10.1038/ng879.CrossRefPubMed Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, de Snoo A, Oldenburg R, Hollestelle A, Houben M, Crepin E, van Veghel-Plandsoen M, et al: Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet. 2002, 31: 55-59. 10.1038/ng879.CrossRefPubMed
7.
go back to reference Finkel E: Australia takes two-step approach on genetic studies. Science. 1998, 280: 1831-1832. 10.1126/science.280.5371.1831.CrossRefPubMed Finkel E: Australia takes two-step approach on genetic studies. Science. 1998, 280: 1831-1832. 10.1126/science.280.5371.1831.CrossRefPubMed
8.
go back to reference Osborne RH, Hopper JL, Kirk JA, Chenevix-Trench G, Thorne HJ, Sambrook JF: kConFab: a research resource of Australasian breast cancer families. Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer [letter]. Med J Aust. 2000, 172: 463-464.PubMed Osborne RH, Hopper JL, Kirk JA, Chenevix-Trench G, Thorne HJ, Sambrook JF: kConFab: a research resource of Australasian breast cancer families. Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer [letter]. Med J Aust. 2000, 172: 463-464.PubMed
10.
go back to reference McCredie MR, Dite GS, Giles GG, Hopper JL: Breast cancer in Australian women under the age of 40. Cancer Causes Control. 1998, 9: 189-198. 10.1023/A:1008886328352.CrossRefPubMed McCredie MR, Dite GS, Giles GG, Hopper JL: Breast cancer in Australian women under the age of 40. Cancer Causes Control. 1998, 9: 189-198. 10.1023/A:1008886328352.CrossRefPubMed
11.
go back to reference John EM, Hopper JL, Beck JC, Knight JA, Neuhausen SL, Senie RT, Ziogas A, Andrulis IL, Anton-Culver H, Boyd N, et al: The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer. Breast Cancer Res. 2004, 6: R375-389. 10.1186/bcr801.CrossRefPubMedPubMedCentral John EM, Hopper JL, Beck JC, Knight JA, Neuhausen SL, Senie RT, Ziogas A, Andrulis IL, Anton-Culver H, Boyd N, et al: The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer. Breast Cancer Res. 2004, 6: R375-389. 10.1186/bcr801.CrossRefPubMedPubMedCentral
14.
go back to reference Lum A, Le Marchand L: A simple mouthwash method for obtaining genomic DNA in molecular epidemiological studies. Cancer Epidemiol Biomarkers Prev. 1998, 7: 719-724.PubMed Lum A, Le Marchand L: A simple mouthwash method for obtaining genomic DNA in molecular epidemiological studies. Cancer Epidemiol Biomarkers Prev. 1998, 7: 719-724.PubMed
16.
go back to reference Xiao W, Oefner PJ: Denaturing high-performance liquid chromatography: A review. Hum Mutat. 2001, 17: 439-474. 10.1002/humu.1130.CrossRefPubMed Xiao W, Oefner PJ: Denaturing high-performance liquid chromatography: A review. Hum Mutat. 2001, 17: 439-474. 10.1002/humu.1130.CrossRefPubMed
17.
go back to reference Hogervorst FB, Nederlof PM, Gille JJ, McElgunn CJ, Grippeling M, Pruntel R, Regnerus R, van Welsem T, van Spaendonk R, Menko FH, et al: Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method. Cancer Res. 2003, 63: 1449-1453.PubMed Hogervorst FB, Nederlof PM, Gille JJ, McElgunn CJ, Grippeling M, Pruntel R, Regnerus R, van Welsem T, van Spaendonk R, Menko FH, et al: Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method. Cancer Res. 2003, 63: 1449-1453.PubMed
19.
go back to reference Chenevix-Trench G, Spurdle AB, Gatei M, Kelly H, Marsh A, Chen X, Donn K, Cummings M, Nyholt D, Jenkins MA, et al: Dominant negative ATM mutations in breast cancer families. J Natl Cancer Inst. 2002, 94: 205-215.CrossRefPubMed Chenevix-Trench G, Spurdle AB, Gatei M, Kelly H, Marsh A, Chen X, Donn K, Cummings M, Nyholt D, Jenkins MA, et al: Dominant negative ATM mutations in breast cancer families. J Natl Cancer Inst. 2002, 94: 205-215.CrossRefPubMed
21.
go back to reference Lakhani SR, Jacquemier J, Sloane JP, Gusterson BA, Anderson TJ, van de Vijver MJ, Farid LM, Venter D, Antoniou A, Storfer-Isser A, et al: Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst. 1998, 90: 1138-1145. 10.1093/jnci/90.15.1138.CrossRefPubMed Lakhani SR, Jacquemier J, Sloane JP, Gusterson BA, Anderson TJ, van de Vijver MJ, Farid LM, Venter D, Antoniou A, Storfer-Isser A, et al: Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst. 1998, 90: 1138-1145. 10.1093/jnci/90.15.1138.CrossRefPubMed
23.
go back to reference Tyrer J, Duffy SW, Cuzick J: A breast cancer prediction model incorporating familial and personal risk factors. Stat Med. 2004, 23: 1111-1130. 10.1002/sim.1668.CrossRefPubMed Tyrer J, Duffy SW, Cuzick J: A breast cancer prediction model incorporating familial and personal risk factors. Stat Med. 2004, 23: 1111-1130. 10.1002/sim.1668.CrossRefPubMed
26.
go back to reference Marsh A, Spurdle AB, Turner BC, Fereday S, Thorne H, Pupo GM, Mann GJ, Hopper JL, Sambrook JF, Chenevix-Trench G: The intronic G13964C variant in p53 is not a high-risk mutation in familial breast cancer in Australia. Breast Cancer Res. 2001, 3: 346-349. 10.1186/bcr319.CrossRefPubMedPubMedCentral Marsh A, Spurdle AB, Turner BC, Fereday S, Thorne H, Pupo GM, Mann GJ, Hopper JL, Sambrook JF, Chenevix-Trench G: The intronic G13964C variant in p53 is not a high-risk mutation in familial breast cancer in Australia. Breast Cancer Res. 2001, 3: 346-349. 10.1186/bcr319.CrossRefPubMedPubMedCentral
27.
go back to reference Wang WW, Spurdle AB, Kolachana P, Bove B, Modan B, Ebbers SM, Suthers G, Tucker MA, Kaufman DJ, Doody MM, et al: A single nucleotide polymorphism in the 5' untranslated region of RAD51 and risk of cancer among BRCA1/2 mutation carriers. Cancer Epidemiol Biomarkers Prev. 2001, 10: 955-960.PubMed Wang WW, Spurdle AB, Kolachana P, Bove B, Modan B, Ebbers SM, Suthers G, Tucker MA, Kaufman DJ, Doody MM, et al: A single nucleotide polymorphism in the 5' untranslated region of RAD51 and risk of cancer among BRCA1/2 mutation carriers. Cancer Epidemiol Biomarkers Prev. 2001, 10: 955-960.PubMed
28.
go back to reference Butow PN, Hiller J, Price M, Thackaway S, Kricker A, Tennant C: Empirical evidence for a relationship between life events, coping style and personality factors in the development of breast cancer. J Psychosom Res. 2000, 49: 169-181. 10.1016/S0022-3999(00)00156-2.CrossRefPubMed Butow PN, Hiller J, Price M, Thackaway S, Kricker A, Tennant C: Empirical evidence for a relationship between life events, coping style and personality factors in the development of breast cancer. J Psychosom Res. 2000, 49: 169-181. 10.1016/S0022-3999(00)00156-2.CrossRefPubMed
29.
go back to reference Butow P, Davenport T, Bennett B, Meiser B, Hickie I, Tucker K, Price M, kCoNFab: Psychological morbidity in women at increased risk of developing breast cancer: a controlled study. Psychooncology. 2005, 14: 196-203. 10.1002/pon.835.CrossRefPubMed Butow P, Davenport T, Bennett B, Meiser B, Hickie I, Tucker K, Price M, kCoNFab: Psychological morbidity in women at increased risk of developing breast cancer: a controlled study. Psychooncology. 2005, 14: 196-203. 10.1002/pon.835.CrossRefPubMed
30.
go back to reference Thompson D, Szabo CI, Mangion J, Oldenburg RA, Odefrey F, Seal S, Barfoot R, Kroeze-Jansema K, Teare D, Rahman N, et al: Evaluation of linkage of breast cancer to the putative BRCA3 locus on chromosome 13q21 in 128 multiple case families from the Breast Cancer Linkage Consortium. Proc Natl Acad Sci USA. 2002, 99: 827-831. 10.1073/pnas.012584499.CrossRefPubMedPubMedCentral Thompson D, Szabo CI, Mangion J, Oldenburg RA, Odefrey F, Seal S, Barfoot R, Kroeze-Jansema K, Teare D, Rahman N, et al: Evaluation of linkage of breast cancer to the putative BRCA3 locus on chromosome 13q21 in 128 multiple case families from the Breast Cancer Linkage Consortium. Proc Natl Acad Sci USA. 2002, 99: 827-831. 10.1073/pnas.012584499.CrossRefPubMedPubMedCentral
31.
go back to reference Scott CL, Jenkins MA, Southey MC, Davis TA, Leary JA, Easton DF, Phillips KA, Hopper JL: Average age-specific cumulative risk of breast cancer according to type and site of germline mutations in BRCA1 and BRCA2 estimated from multiple-case breast cancer families attending Australian family cancer clinics. Hum Genet. 2003, 112: 542-551.PubMed Scott CL, Jenkins MA, Southey MC, Davis TA, Leary JA, Easton DF, Phillips KA, Hopper JL: Average age-specific cumulative risk of breast cancer according to type and site of germline mutations in BRCA1 and BRCA2 estimated from multiple-case breast cancer families attending Australian family cancer clinics. Hum Genet. 2003, 112: 542-551.PubMed
32.
go back to reference Scott CI, Iorgulescu DG, Thorne HJ, Henderson MA, Phillips KA: Clinical, pathological and genetic features of women at high familial risk of breast cancer undergoing prophylactic mastectomy. Clin Genet. 2003, 64: 111-121. 10.1034/j.1399-0004.2003.00097.x.CrossRefPubMed Scott CI, Iorgulescu DG, Thorne HJ, Henderson MA, Phillips KA: Clinical, pathological and genetic features of women at high familial risk of breast cancer undergoing prophylactic mastectomy. Clin Genet. 2003, 64: 111-121. 10.1034/j.1399-0004.2003.00097.x.CrossRefPubMed
33.
go back to reference Southey MC, Tesoriero A, Young MA, Holloway AJ, Jenkins MA, Whitty J, Misfud S, kConFab, McLachlan SA, Venter DJ, et al: A specific GFP expression assay, penetrance estimate, and histological assessment for a putative splice site mutation in BRCA1. Hum Mutat. 2003, 22: 86-91. 10.1002/humu.10224.CrossRefPubMed Southey MC, Tesoriero A, Young MA, Holloway AJ, Jenkins MA, Whitty J, Misfud S, kConFab, McLachlan SA, Venter DJ, et al: A specific GFP expression assay, penetrance estimate, and histological assessment for a putative splice site mutation in BRCA1. Hum Mutat. 2003, 22: 86-91. 10.1002/humu.10224.CrossRefPubMed
34.
go back to reference Meiser B, Butow P, Price M, Bennett B, Berry G, Tucker K: Attitudes to prophylactic surgery and chemoprevention in Australian women at increased risk for breast cancer. J Womens Health (Larchmt). 2003, 12: 769-778.CrossRef Meiser B, Butow P, Price M, Bennett B, Berry G, Tucker K: Attitudes to prophylactic surgery and chemoprevention in Australian women at increased risk for breast cancer. J Womens Health (Larchmt). 2003, 12: 769-778.CrossRef
35.
go back to reference Lim J, Macluran M, Price M, Bennett B, Butow P, kCoNFab: Short and long-term impact of receiving genetic mutation results in women at increased risk for hereditary breast cancer. J Genet Couns. 2004, 13: 115-133. 10.1023/B:JOGC.0000018822.56297.a6.CrossRefPubMed Lim J, Macluran M, Price M, Bennett B, Butow P, kCoNFab: Short and long-term impact of receiving genetic mutation results in women at increased risk for hereditary breast cancer. J Genet Couns. 2004, 13: 115-133. 10.1023/B:JOGC.0000018822.56297.a6.CrossRefPubMed
36.
go back to reference Mote PA, Leary JA, Avery KA, Sandelin K, Chenevix-Trench G, Kirk JA, Clarke CL: Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A. Genes Chromosomes Cancer. 2004, 39: 236-248. 10.1002/gcc.10321.CrossRefPubMed Mote PA, Leary JA, Avery KA, Sandelin K, Chenevix-Trench G, Kirk JA, Clarke CL: Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A. Genes Chromosomes Cancer. 2004, 39: 236-248. 10.1002/gcc.10321.CrossRefPubMed
37.
go back to reference Campbell IG, Choong D, Chenevix-Trench G: No germline mutations in the histone acetyltransferase gene EP300 in BRCA1 and BRCA2 negative families with breast cancer and gastric, pancreatic, or colorectal cancer. Breast Cancer Res. 2004, 6: R366-371. 10.1186/bcr803.CrossRefPubMedPubMedCentral Campbell IG, Choong D, Chenevix-Trench G: No germline mutations in the histone acetyltransferase gene EP300 in BRCA1 and BRCA2 negative families with breast cancer and gastric, pancreatic, or colorectal cancer. Breast Cancer Res. 2004, 6: R366-371. 10.1186/bcr803.CrossRefPubMedPubMedCentral
Metadata
Title
Analysis of cancer risk and BRCA1 and BRCA2mutation prevalence in the kConFab familial breast cancer resource
Authors
Graham J Mann
Heather Thorne
Rosemary L Balleine
Phyllis N Butow
Christine L Clarke
Edward Edkins
Gerda M Evans
Sián Fereday
Eric Haan
Michael Gattas
Graham G Giles
Jack Goldblatt
John L Hopper
Judy Kirk
Jennifer A Leary
Geoffrey Lindeman
Eveline Niedermayr
Kelly-Anne Phillips
Sandra Picken
Gulietta M Pupo
Christobel Saunders
Clare L Scott
Amanda B Spurdle
Graeme Suthers
Kathy Tucker
Georgia Chenevix-Trench
The Kathleen Cuningham Consortium for Research in Familial Breast Cancer
Publication date
01-02-2006
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2006
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr1377

Other articles of this Issue 1/2006

Breast Cancer Research 1/2006 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine